GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Amcad Biomed Corp (ROCO:4188) » Definitions » Price-to-Free-Cash-Flow

Amcad Biomed (ROCO:4188) Price-to-Free-Cash-Flow : N/A (As of Jun. 02, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Amcad Biomed Price-to-Free-Cash-Flow?

As of today (2024-06-02), Amcad Biomed's share price is NT$26.35. Amcad Biomed's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was NT$-0.79. Hence, Amcad Biomed's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Amcad Biomed's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 13 years, Amcad Biomed's highest Price-to-Free-Cash-Flow Ratio was 46.43. The lowest was 5.36. And the median was 24.58.

ROCO:4188's Price-to-Free-Cash-Flow is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 34.365
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Amcad Biomed's Free Cash Flow per Share for the three months ended in Mar. 2024 was NT$-0.29. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was NT$-0.79.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 6.00% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 17.40% per year.

During the past 13 years, Amcad Biomed's highest 3-Year average Free Cash Flow per Share Growth Rate was 32.80% per year. The lowest was -17.40% per year. And the median was 6.25% per year.


Amcad Biomed Price-to-Free-Cash-Flow Historical Data

The historical data trend for Amcad Biomed's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amcad Biomed Price-to-Free-Cash-Flow Chart

Amcad Biomed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Amcad Biomed Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Amcad Biomed's Price-to-Free-Cash-Flow

For the Medical Devices subindustry, Amcad Biomed's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amcad Biomed's Price-to-Free-Cash-Flow Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Amcad Biomed's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Amcad Biomed's Price-to-Free-Cash-Flow falls into.



Amcad Biomed Price-to-Free-Cash-Flow Calculation

Amcad Biomed's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=26.35/-0.792
=N/A

Amcad Biomed's Share Price of today is NT$26.35.
Amcad Biomed's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-0.79.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Amcad Biomed  (ROCO:4188) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Amcad Biomed Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Amcad Biomed's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Amcad Biomed (ROCO:4188) Business Description

Traded in Other Exchanges
N/A
Address
No. 167, Fuxing North Road, 5th Floor, Zhongshan District, Taipei, TWN, 104
Amcad Biomed Corp develops computer-aided detection and diagnosis(CADe/CADx) software devices. Its product pipeline includes AmCAD-UT Detection, a software solution for thyroid nodules analysis; AmCAD-UV, a software device that is used for quantifying and classifying the ultrasonic color intensity data acquired from FDA-cleared ultrasound systems and displaying the noise-reduced color-coded pulsatile signals; AmCAD- U.S, a software device for viewing and quantifying ultrasound image data of backscattered signals; and AmCAD-UO offers detection for obstructive sleep apnea on awake patients to identify the root cause of sleep apnea. The company's geographical segments include Taiwan, China, and other countries, out of which the majority of the revenue is generated from China.

Amcad Biomed (ROCO:4188) Headlines

No Headlines